David C. Schultz

David C. Schultz

Auto-generated profile, based on publicly available information

David C. Schultz


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Nature
Verified
Journal Article
Closed access
PDF file
DSDavid C. Schultz
David C. Schultz
RJRobert M. Johnson
Robert M. Johnson
KAKasirajan Ayyanathan
Kasirajan Ayyanathan
JMJesse Miller
Jesse Miller
KWKanupriya Whig
Kanupriya Whig
SCSara Cherry
Sara Cherry

28 May 2021 in Science Immunology
Verified
Journal Article
Open access
PDF file
MLMinghua Li
Minghua Li
MFMax Ferretti
Max Ferretti
BYBaoling Ying
Baoling Ying
HDHélène Descamps
Hélène Descamps
ELEmily Lee
Emily Lee
SCSara Cherry
Sara Cherry
Pharmacological activation of STING blocks SARS-CoV-2 infection including variants of concern in vitro and in vivo.

29 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYong Gu Lee
Yong Gu Lee
PGPuneeth Guruprasad
Puneeth Guruprasad
GGGuido Ghilardi
Guido Ghilardi
RPRaymone Pajarillo
Raymone Pajarillo
CSChristopher Tor Sauter
Christopher Tor Sauter
MRMarco Ruella
Marco Ruella
Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two thirds of patients experience treatment failure. Resistance to apoptosis is a key feature of cancer cells, and it is associated with treatment failure. In 87 patients with NHL treated with anti-CD19 CART, we found that chromosomal alteration of B-cell lymphoma 2 (BCL-2), a critical antiapoptotic regulator, in lymphoma cells was associated with reduced survival. Therefore, we combined CART19 with the FDA-approved BCL-2 inhibitor venetoclax and demonstrated in vivo synergy in venetoclax-sensitive NHL. However, higher venetoclax doses needed for venetoclax-resistant lymphomas resulted in CART toxicity. To overcome this limitation, we developed venetoclax-resistant CART by overexpressing mutated BCL-2(F104L), which is not recognized by venetoclax. Notably, BCL-2(F104L)-CART19 synergized with venetoclax in multiple lymphoma xenograft models. Furthermore, we uncovered that BCL-2 overexpression in T cells intrinsically enhanced CART antitumor activity in preclinical models and in patients by prolonging CART persistence. Significance: This study highlights the role of BCL-2 in resistance to CART immunotherapy for cancer and introduces a novel concept for combination therapies—the engineering of CART cells to make them resistant to proapoptotic small molecules, thereby enhancing the therapeutic index of these combination therapies. This article is highlighted in the In This Issue feature, p. 2221

30 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
XLXiaolei Liu
Xiaolei Liu
AVAnurag Verma
Anurag Verma
GGGustavo Garcia
Gustavo Garcia
HRHolly Ramage
Holly Ramage
ALAnastasia Lucas
Anastasia Lucas
PKPeter S. Klein
Peter S. Klein
The coronaviruses responsible for severe acute respiratory syndrome (SARS-CoV), COVID-19 (SARS-CoV-2), Middle East respiratory syndrome-CoV, and other coronavirus infections express a nucleocapsid protein (N) that is essential for viral replication, transcription, and virion assembly. Phosphorylation of N from SARS-CoV by glycogen synthase kinase 3 (GSK-3) is required for its function and inhibition of GSK-3 with lithium impairs N phosphorylation, viral transcription, and replication. Here we report that the SARS-CoV-2 N protein contains GSK-3 consensus sequences and that this motif is conserved in diverse coronaviruses, raising the possibility that SARS-CoV-2 may be sensitive to GSK-3 inhibitors, including lithium. We conducted a retrospective analysis of lithium use in patients from three major health systems who were PCR-tested for SARS-CoV-2. We found that patients taking lithium have a significantly reduced risk of COVID-19 (odds ratio = 0.51 [0.35–0.74], P = 0.005). We also show that the SARS-CoV-2 N protein is phosphorylated by GSK-3. Knockout of GSK3A and GSK3B demonstrates that GSK-3 is essential for N phosphorylation. Alternative GSK-3 inhibitors block N phosphorylation and impair replication in SARS-CoV-2 infected lung epithelial cells in a cell-type–dependent manner. Targeting GSK-3 may therefore provide an approach to treat COVID-19 and future coronavirus outbreaks. Significance COVID-19 is taking a major toll on personal health, healthcare systems, and the global economy. With three betacoronavirus epidemics in less than 20 y, there is an urgent need for therapies to combat new and existing coronavirus outbreaks. Our analysis of clinical data from over 300,000 patients in three major health systems demonstrates a 50% reduced risk of COVID-19 in patients taking lithium, a direct inhibitor of glycogen synthase kinase-3 (GSK-3). We further show that GSK-3 is essential for phosphorylation of the SARS-CoV-2 nucleocapsid protein and that GSK-3 inhibition blocks SARS-CoV-2 infection in human lung epithelial cells. These findings suggest an antiviral strategy for COVID-19 and new coronaviruses that may arise in the future.

24 January 2024 in Nature Aging
Verified
Journal Article
Closed access
PDF file
XHXue Hao
Xue Hao
BZBo Zhao
Bo Zhao
MTMartina Towers
Martina Towers
LLLiping Liao
Liping Liao
EMEdgar Luzete Monteiro
Edgar Luzete Monteiro
RZRugang Zhang
Rugang Zhang

13 March 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TGTyler A. Garretson
Tyler A. Garretson
JLJiaojiao Liu
Jiaojiao Liu
SLShuk Hang Li
Shuk Hang Li
GSGabrielle Scher
Gabrielle Scher
JSJefferson Santos
Jefferson Santos
SHScott E. Hensley
Scott E. Hensley